文献速递精神分裂症与精神病性障碍

滴定速度、性别、肥胖及合并用药对日本精神分裂症患者氯氮平相关发热风险及发热出现时间的影响:21家医院病历回顾性审查

Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals.
PubMed 文献 · Br J Psychiatry · 2024-01-01

该研究为病例对照研究,回顾性调查2010至2022年间日本21家医院首次接受氯氮平的539例治疗抵抗性精神分裂症患者病历,其中512例纳入分析。按国际指南针对东亚人群推荐的滴定速率分为较快、较慢和超慢三组,采用逻辑回归分析发热(37.5°C及以上持续至少2天)风险的解释变量。结果显示较快滴定、男性性别及合并使用丙戊酸或喹硫平显著增加发热风险,较快滴定时发热出现更早,肥胖为加速发热出现的因素。

要点

  • 较快滴定速度、男性性别及合并使用丙戊酸或喹硫平与氯氮平相关发热风险显著增加相关。
  • 较快滴定时发热出现时间显著更早,肥胖为加速发热出现的因素。
  • 合并使用奥氮平、锂盐或食欲素受体拮抗剂未检测到发热风险增加。

核心结论

  • 较快滴定速度及氯氮平起始时合并使用丙戊酸和喹硫平增加氯氮平相关发热风险。
  • 临床医生应谨慎滴定氯氮平,并同时考虑滴定速度和合并用药。

研究设计与样本

  • 病例对照研究,回顾性调查2010至2022年间日本21家医院首次接受氯氮平的539例治疗抵抗性精神分裂症患者病历,512例纳入分析。
  • 按国际指南针对东亚人群推荐的滴定速率分为较快滴定组、较慢滴定组和超慢滴定组。
  • 全面调查氯氮平起始时合并用药(如抗精神病药、心境稳定剂、催眠药和抗焦虑药)情况。
  • 采用逻辑回归分析识别37.5°C及以上持续至少2天发热风险的解释变量。

主要发现

  • 发热风险随较快滴定、男性性别及合并使用丙戊酸或喹硫平显著增加。
  • 合并使用奥氮平、锂盐或食欲素受体拮抗剂等其他药物未检测到发热风险增加。
  • 较快滴定时发热出现显著更早。
  • 多因素分析确定肥胖为加速发热出现的因素。

关键数值与推荐

  • 发热定义为37.5°C及以上持续至少2天。
  • 按国际指南针对东亚人群推荐的滴定速率分为较快滴定组、较慢滴定组和超慢滴定组。

临床怎么用

  • 临床医生应谨慎滴定氯氮平,并同时考虑滴定速度和合并用药。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Clozapine-induced inflammation, such as myocarditis and pneumonia, can occur during initial titration and can be fatal. Fever is often the first sign of severe inflammation, and early detection and prevention are essential. Few studies have investigated the effects of clozapine titration speed and concomitant medication use on the risk of clozapine-induced inflammation. AIMS: We evaluated the risk factors for clozapine-associated fever, including titration speed, concomitant medication use, gender and obesity, and their impact on the risk of fever and the fever onset date. METHOD: We conducted a case-control study. The medical records of 539 Japanese participants with treatment-resistant schizophrenia at 21 hospitals in Japan who received clozapine for the first time between 2010 and 2022 were retrospectively investigated. Of these, 512 individuals were included in the analysis. Individuals were divided into three groups according to the titration rate recommended by international guidelines for East Asians: the faster titration group, the slower titration group and the ultra-slower titration group. The use of concomitant medications (such as antipsychotics, mood stabilisers, hypnotics and anxiolytics) at clozapine initiation was comprehensively investigated. Logistic regression analysis was performed to identify the explanatory variables for the risk of a fever of 37.5°C or higher lasting at least 2 days. RESULTS: Fever risk significantly increased with faster titration, male gender and concomitant use of valproic acid or quetiapine. No increased fever risk was detected with the use of other concomitant drugs, such as olanzapine, lithium or orexin receptor antagonists. Fever onset occurred significantly earlier with faster titration. Multivariate analysis identified obesity as being a factor that accelerated fever onset. CONCLUSION: A faster titration speed and concomitant treatment with valproic acid and quetiapine at clozapine initiation increased the risk of clozapine-associated fever. Clinicians should titrate clozapine with caution and consider both the titration speed and concomitant medications.

来源:Br J Psychiatry,查看原文。版权归原作者所有。

引用

  1. Kikuchi Y, Kurosawa M, Sakata M, et al. Effects of titration speed, gender, obesity and concomitant medications on the risk and onset time of clozapine-associated fever among Japanese patients with schizophrenia: retrospective review of charts from 21 hospitals. Br J Psychiatry. 2024. PMID: 39104017. doi:10.1192/bjp.2024.113

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。